Medically reviewed by Drugs.com. Last updated on Sep 11, 2019.
(si DOF o veer)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Intravenous [preservative free]:
Generic: 75 mg/mL (5 mL)
- Antiviral Agent
Cidofovir is converted to cidofovir diphosphate (the active intracellular metabolite); cidofovir diphosphate suppresses CMV replication by selective inhibition of viral DNA synthesis. Incorporation of cidofovir diphosphate into growing viral DNA chain results in viral DNA synthesis rate reduction.
Vd: 0.41 L/kg; does not cross significantly into CSF
Minimal; phosphorylation occurs intracellularly to the active metabolite cidofovir diphosphate
Urine (70% to 85% as unchanged drug)
Renal clearance without probenecid: 150 ± 26.9 mL/minute/1.73 m2
Renal clearance with probenecid: 98.6 ± 27.9 mL/minute/1.73 m2
Plasma: ~2.6 hours; intracellular elimination half-lives of metabolites are longer (range: 24 to 87 hours) (Lea, 1996)
Special Populations: Renal Function Impairment
Clearance decreases proportionally with CrCl.
Use: Labeled Indications
Cytomegalovirus retinitis: Treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.
Limitations of use: Safety and efficacy have not been established for treatment of other CMV infections (eg, pneumonitis, gastroenteritis), congenital or neonatal CMV disease, or CMV disease in non-HIV infected individuals.
Off Label Uses
Herpes simplex virus (HSV) infection, acyclovir-resistant:
Data from case reports in immunocompromised patients (stem cell transplant recipients) suggest that intravenous cidofovir may be effective for acyclovir-resistant HSV type 1 mucosal infections [Andrei 2007], [Chen 2000], [LoPresti 1998]. A review article suggested that intravenous cidofovir be reserved for use following treatment failure with intravenous foscarnet due to concerns of cidofovir-associated toxicity [Levin 2004]. Additional trials may be necessary to further define the role of cidofovir in acyclovir-resistant HSV infections.
Based on the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, intravenous cidofovir might be effective as an alternative agent to intravenous foscarnet for the treatment of acyclovir-resistant HSV infections, although limited evidence is available and more studies are needed.
Data from a small number of immunocompromised AIDS patients in a randomized, double-blind, placebo-controlled trial suggest that topical cidofovir gel (not commercially available in the US) may be beneficial for the treatment of acyclovir-resistant mucocutaneous HSV infections [Lalezari 1997]. Additional trials may be necessary to further define the role of topical cidofovir in this condition. Review articles suggested that for skin lesions, topical cidofovir may offer the advantage of limiting cidofovir exposure and reduce the potential for cidofovir-associated toxicity and resistance [Levin 2004], [Lingappa 2007].
Based on the Centers for Disease Control and Prevention (CDC) sexually transmitted diseases treatment guidelines, topical cidofovir 1 % gel might be effective as an alternative agent for the treatment of acyclovir-resistant HSV infections, although limited evidence is available and more studies are needed.
Hypersensitivity to cidofovir or any component of the formulation; history of clinically-severe hypersensitivity to probenecid or other sulfa-containing medications; serum creatinine >1.5 mg/dL; CrCl ≤55 mL/minute; urine protein ≥100 mg/dL (≥2+ proteinuria); use with or within 7 days of nephrotoxic agents; direct intraocular injection
Cytomegalovirus (CMV) retinitis: IV:
Induction: 5 mg/kg/dose with concomitant probenecid once weekly for 2 consecutive weeks
Maintenance: 5 mg/kg/dose with concomitant probenecid once every 2 weeks
Probenecid: 2 g 3 hours prior to cidofovir dose, then 1 g at 2 hours and 8 hours after completion of the infusion.
Hydration: Patients should also receive 1 L of NS intravenously infused over 1 to 2 hours immediately prior to each cidofovir infusion. If tolerated, a second liter may be administered over 1 to 3 hours at the start of cidofovir infusion or immediately following infusion.
Herpes simplex virus (HSV) infection, acyclovir-resistant (off-label use):
IV: Mucosal infections: 5 mg/kg/dose once weekly for 3 weeks (Andrei 2007; Chen 2000; LoPresti, 1998), then 5 mg/kg/dose once every 2 weeks for 3 doses (Andrei 2007). Concomitant oral probenecid and hydration has been used to reduce the risk of cidofovir-associated nephrotoxicity (LoPresti 1998)
Topical (off-label route): Mucocutaneous infections: Apply cidofovir 1% gel (extemporaneously prepared by a compounding pharmacy) once daily for 5 days (CDC [Workowski 2015]; Lalezari 1997; Lingappa 2007). Observe for 10 days following treatment; therapy may be repeated if necessary for up to six repetitive cycles (Lalezari 1997)
Refer to adult dosing.
Note: Administration of cidofovir should be accompanied by concomitant oral probenecid and intravenous normal saline hydration; various regimens have been reported (Anderson 2008; Bhadri 2009; Cesaro 2005; Doan 2007; Williams 2009; Yusuf 2006)
Hydration: IV: 20 mL/kg of 0.9% sodium chloride (maximum: 1,000 mL) administered for 1 hour before cidofovir infusion and 20 mL/kg of 0.9% sodium chloride (maximum: 1,000 mL) over 1 hour during cidofovir infusion, followed by 2 hours of maintenance fluids or increase the maintenance fluid infusion rate to 3 times the maintenance rate for 1 hour before cidofovir infusion and continuing until 1 hour after, then decrease to 2 times the maintenance fluid rate for the subsequent 2 hours
Probenecid: Oral: 25 to 40 mg/kg/dose (maximum dose: 2,000 mg) administered 3 hours before cidofovir infusion and 10 to 20 mg/kg/dose (maximum dose: 1,000 mg) at 2 to 3 hours and 8 to 9 hours after cidofovir infusion or 1,000 or 1,250 mg/m2/dose administered 3 hours prior to cidofovir, followed by 500 to 1,250 mg/m2/dose 1 to 2 hours and 8 hours after completion
Adenovirus infection, posthematopoietic stem cell transplant; treatment: Limited data available; optimal dose not defined; specific regimens may vary (Bhadri 2009; Legrand 2001; Yusuf 2006): Infants, Children, and Adolescents:
Induction: IV: 5 mg/kg/dose once weekly for 2 to 3 consecutive weeks (with hydration and probenecid)
Maintenance: IV: 5 mg/kg/dose once every 2 weeks or 3 mg/kg/dose once weekly (with hydration and probenecid) until consecutive negative adenovirus samples. Note: In one study, patients requiring prolonged treatment courses were switched from 3 mg/kg/dose once weekly to 1 mg/kg/dose given 3 times/week (Bhadri 2009)
Adenovirus infection, postlung transplant; treatment: Very limited data available: Infants ≥6 months and Children <3 years: IV: 1 mg/kg/dose every other day or 3 times weekly for 4 consecutive weeks (with hydration and probenecid); dosing from a case series (n=4, age range: 0.5 to 2.6 years) (Doan 2007)
BK virus allograft nephropathy: Limited data available: Children and Adolescents: IV: Initial dose: 0.25 mg/kg/dose every 2 to 3 weeks; dose may be increased if BK virus PCR counts do not decrease 1 log fold to a maximum dose of 1 mg/kg/dose. Dosing based on reported experience from two case series of 10 renal transplant patients (ages: 5 to 21 years). The reported hydration was D51/2NS or D51/4NS for 2 hours before cidofovir and for 2 hours following the infusion; cidofovir was infused over 2 hours and no probenecid was used (Araya 2008; Araya 2010).
BK virus hemorrhagic cystitis after stem cell or bone marrow transplant: Limited data available; optimal dose not established: Children and Adolescents: IV: 5 mg/kg/dose once weekly for 2 to 4 weeks, followed by 5 mg/kg/dose every other week given with probenecid and adequate hydration until cystitis resolved is the most commonly reported dose (Cesaro 2009, Gaziev 2010, Megged 2011). Others have described lower doses of 0.5 to 1 mg/kg/dose given once weekly with or without probenecid (Cesaro 2009; Cesaro 2013; Faraci 2009).
Cytomegalovirus (CMV) infection: Limited data available. IV:
Allogeneic stem cell transplantation recipients: Treatment: Children and Adolescents: Dosing based on reported experience in 10 pediatric patients (2 to 14 years); most patients received cidofovir as second-line therapy following allogeneic stem cell transplantation (Cesaro 2005).
Induction: 5 mg/kg/dose once weekly for 2 consecutive weeks (with hydration, probenecid and antiemetic)
Maintenance: 3 to 5 mg/kg/dose once every 2 weeks for 2 to 4 doses (with hydration, probenecid, and antiemetic)
CMV retinitis: Treatment: Adolescents [DHHS (adult) 2013]:
Induction: 5 mg/kg/dose once weekly for 2 consecutive weeks (with hydration and probenecid)
Maintenance: 5 mg/kg/dose every other week (with hydration and probenecid)
Secondary prophylaxis: 5 mg/kg/dose every other week (with hydration and probenecid) [DHHS (adult/pediatric) 2013]
Respiratory papillomatosis, recurrent: Limited data available: Children and Adolescents: Intralesional: 7.5 mg/mL every 2 weeks until complete remission (Naiman 2006)
Dilute dose in NS 100 mL prior to infusion.
A 1% topical cidofovir gel may be prepared by using 5 mL of the 75 mg/mL cidofovir injection and combining with 32.5 mL of a propylene glycol-based jelly. Of note, propylene glycol may increase the absorption and bioavailability of cidofovir when used on abraded skin (McElhiney 2006).
IV: For IV infusion only. Infuse over 1 hour. Administer with concomitant probenecid. Hydrate with 1 L of NS IV over 1 to 2 hours immediately prior to cidofovir infusion. If tolerated, a second liter may be administered over a 1- to 3-hour period at the start of or immediately following cidofovir infusion.
Topical: Off-label route: An extemporaneously prepared gel may be prepared by a compounding pharmacy and applied topically for mucocutaneous infections (McElhiney 2006).
Store intact vials at 20°C to 25°C (68°F to 77°F). Admixtures in D51/4NS, D5W, or NS may be stored for ≤24 hours under refrigeration; however, admixtures must be administered within 24 hours of preparation.
Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Monitor therapy
Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. Avoid combination
Tenofovir Products: Cidofovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir. Monitor therapy
Frequency not defined. *Incidence not specifically defined, but reported in the range of >10%. **Incidence not specifically defined, but reported in the range of 1% to 10%.
Cardiovascular: Cardiac disease, cardiac failure, cardiomyopathy, edema, orthostatic hypotension, shock, syncope, tachycardia
Central nervous system: Chills,* headache,* pain,* agitation, amnesia, anxiety, confusion, convulsions, dizziness, hallucination, insomnia, malaise, vertigo
Dermatologic: Alopecia,* skin rash,* skin discoloration, skin photosensitivity, urticaria
Endocrine & metabolic: Decreased serum bicarbonate,* Fanconi’s syndrome,** adrenocortical insufficiency
Gastrointestinal: Anorexia,* diarrhea,* nausea,* oral candidiasis,* vomiting,* abdominal pain, aphthous stomatitis, colitis, constipation, dysphagia, fecal incontinence, gastritis, gastrointestinal hemorrhage, gingivitis, melena, proctitis, stomatitis, tongue discoloration
Genitourinary: Nephrotoxicity,* proteinuria,* urinary incontinence
Hematologic & oncologic: Anemia,* neutropenia,* hypochromic anemia, immune thrombocytopenia, leukocytosis, leukopenia, lymphadenopathy, pancytopenia, pseudolymphoma, splenomegaly, thrombocytopenia
Hepatic: Abnormal liver function tests, hepatic disease, hepatic necrosis, hepatomegaly, hepatosplenomegaly, jaundice
Hypersensitivity: Hypersensitivity reaction
Infection: Infection,* sepsis
Local: Injection site reaction
Neuromuscular & skeletal: Weakness,* tremor
Ophthalmic: Decreased intraocular pressure,* iritis,* uveitis,* amblyopia, blindness, cataract, conjunctivitis, corneal lesion, diplopia, visual disturbance
Otic: Hearing loss
Renal: Increased serum creatinine*
Respiratory: Cough,* dyspnea,* pneumonia**
<1%, postmarketing, and/or case reports: Hepatic failure, metabolic acidosis, pancreatitis
ALERT: U.S. Boxed WarningNephrotoxicity:
Renal impairment is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as 1 or 2 doses of cidofovir. To reduce possible nephrotoxicity, IV prehydration with normal saline and administration of probenecid must be used with each cidofovir infusion. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified for changes in renal function as appropriate. Cidofovir is contraindicated in patients who are receiving other nephrotoxic agents.Neutropenia:
Neutropenia has been observed in association with cidofovir treatment. Therefore, neutrophil counts should be monitored during cidofovir therapy.Appropriate use:
Cidofovir is indicated only for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).Carcinogenic/teratogenic:
In animal studies, cidofovir was carcinogenic, teratogenic and caused hypospermia.
Concerns related to adverse effects:
• Carcinogenic/teratogenic: [US Boxed Warning]: Possibly carcinogenic and teratogenic based on animal data. May cause hypospermia.
• Metabolic acidosis: Monitor for signs of metabolic acidosis; decreased sodium bicarbonate with proximal tubule injury and renal wasting syndrome (including Fanconi syndrome), as well as metabolic acidosis with hepatic impairment and pancreatitis (including some fatal cases) have been reported.
• Nephrotoxicity: [US Boxed Warning]: Acute renal failure resulting in dialysis and/or contributing to death has occurred with as few as 1 or 2 doses of cidofovir. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir and the dose of cidofovir modified as appropriate. Administration must be accompanied by oral probenecid and intravenous saline prehydration.
• Neutropenia: [US Boxed Warning]: Neutropenia has been reported; monitor neutrophil counts during therapy.
• Ocular complications: Decreased intraocular pressure, sometimes associated with decreased visual acuity, uveitis, or iritis may occur; monitor intraocular pressure for and signs of iritis/uveitis during therapy. If uveitis or iritis occurs, consider treatment with topical corticosteroids with or without topical cycloplegic agents.
• Renal impairment: Contraindicated in patients with a baseline serum creatinine >1.5 mg/dL, CrCl ≤55 mL/minute, or urine protein ≥100 mg/dL (≥2+ proteinuria); dosage adjustment or discontinuation of therapy may be required for changes in renal function during treatment.
• Administration: For intravenous use only, not for direct intraocular injection; iritis, ocular hypotony, and permanent impairment of vision may occur.
• Appropriate use: [US Boxed Warning]: Indicated only for CMV retinitis treatment in patients with AIDS.
Serum creatinine and urine protein (at baseline and within 48 hours of each dose), WBC with differential (prior to each dose); intraocular pressure and visual acuity, signs and symptoms of uveitis/iritis; metabolic acidosis.
Pregnancy Risk Factor
[US Boxed Warning]: In animal studies, cidofovir was teratogenic and caused hypospermia.
The indications for treating CMV retinitis during pregnancy are the same as in nonpregnant HIV infected woman; however, systemic therapy should be avoided during the first trimester when possible. When therapy is needed to treat maternal infection, agents other than cidofovir are recommended (DHHS [Adult OI 2014]).
Women of childbearing potential should use effective contraception during therapy and for 1 month following treatment. Males should use a barrier contraceptive during therapy and for 3 months following treatment.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience headache, diarrhea, lack of appetite, hair loss, vomiting, or nausea. Have patient report immediately to prescriber signs of kidney problems (unable to pass urine, blood in the urine, change in amount of urine passed, or weight gain), signs of infection, signs of lactic acidosis (fast breathing, fast heartbeat, abnormal heartbeat, vomiting, fatigue, shortness of breath, severe loss of strength and energy, severe dizziness, feeling cold, or muscle pain or cramps), signs of pancreatitis (severe abdominal pain, severe back pain, severe nausea, or vomiting), signs of liver problems (dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin), vision changes, eye pain, severe eye irritation, shortness of breath, severe loss of strength and energy, or thrush (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about cidofovir
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: purine nucleosides
- FDA Alerts (1)
Other brands: Vistide